^
Association details:
| Biomarker: | Chr amplification(11)(q13) |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma
Published date:
03/28/2023
Excerpt:
In the PD-1Ab group, the median progression-free survival (PFS) was 1.5 months in Amp11q13 patients vs 16.2 months in non-Amp11q13 patients (HR, 0.05; 95% CI 0.01-0.45; P = 0.0003)….HCC patients with Amp11q13 are less likely to benefit from PD-1 blockade therapies.
DOI:
10.3389/fimmu.2023.1116057
